Form 4: PepGen Director Heidi Henson Acquires 16,000 Stock Options

PepGen Inc. Director Heidi Henson has acquired 16,000 stock options with an exercise price of $1.51, which are set to vest fully by June 4, 2026, or the date of the next Annual Meeting.

Summary

• Heidi Henson, a Director of PepGen Inc. (PEPG), acquired 16,000 stock options on June 4, 2025.
• The exercise price for these options is $1.51 per share.
• The options will vest in full upon the earlier of June 4, 2026 (the first anniversary of the grant date) or the date of the next Annual Meeting.
• Vesting is contingent on Ms. Henson's continued service as a director, unless the Board of Directors determines otherwise.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Ms. Henson directly beneficially owns 16,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $1.51 provides a clear benchmark for the value at which the options can be converted into common stock.

Risks

• The vesting of the options is conditional on the individual's continued service as a director, meaning the options could be forfeited if Ms. Henson ceases to serve on the board before vesting, unless the Board determines otherwise.
• The value of the options is dependent on the future market price of PepGen Inc.'s common stock exceeding the exercise price of $1.51.

Future Outlook

The acquisition of these stock options indicates a future potential increase in the number of outstanding common shares if the options are exercised, which is contingent on the company's stock performance and the director's continued service.

Industry Context

The grant of stock options is a common form of equity compensation for directors in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, aiming to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard component of compensation packages across various industries, including biotech, to attract and retain qualified board members.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity grants, similar to practices observed at companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which also utilize equity-based compensation to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options from PepGen Inc. to Heidi Henson, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest in full upon the earlier of June 4, 2026, or the date of the next Annual Meeting.
• Upon vesting, the director will have the right to exercise these options at the specified price of $1.51 per share until the expiration date of June 3, 2035.

Key Dates

Recommendation

Keywords

PepGen Inc., PEPG, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Heidi Henson, SEC Filing